BioCentury

7:00 AM GMT, Aug 24, 2015
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Analyst picks & changes
CompanyBankAnalystCoverageOpinionWk chg8/21 cls
Avalanche Biotechnologies Inc. (NASDAQ:AAVL)Chardan CapitalGbola AmusaUpgradeBuy (from neutral)6%$10.62
Amusa upgraded, saying the stock has "oversold below rational levels based on cash/share, technology value, and also M&A considerations." On Aug. 14, the stock dropped 28% after the company said it will not begin a

Read the full 513 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.